



Provider Update

Date: October 25, 2018 To: Well Sense Health Plan Network Providers

The following Well Sense Health Plan medical policies have been updated, and the revised documents will be **effective January 1, 2019**.

- Ambulatory Cardiac Monitors (Excluding Holter Monitoring), OCA 3.35
- Biofeedback in an Outpatient Setting to Treat Bladder and/or Bowel Dysfunction (including incontinence), OCA 3.969
- Car T-Cell Therapy with KYMRIA or YESCARTA to Treat Hematological Malignancies, OCA 3.22
- Continuous Glucose Monitoring Systems (CGMS) and Insulin Delivery Systems, OCA 3.966
- Posterior Tibial Nerve Stimulation (Percutaneous or Transcutaneous), OCA 3.562
- Sacral Nerve Stimulation (including Peripheral Nerve Stimulation Test and Two Stage Tined Lead Procedure) for Incontinence and Urinary Conditions, OCA 3.563

These policies, criteria and prior authorization requirements are applicable to all Well Sense Health Plan members. All Well Sense medical policies are located on the [Provider's page at Wellsense.org under the Policies link](#). If you do not have Web access, contact your Provider Relations Consultant for a copy of the policies.



1155 Elm Street, Suite 600
Manchester, NH 03101
WellSense.org

Presorted
First Class
U.S. Postage
PAID
Permit No. 1520
Boston, MA